IP Library Granted Patent US 9,980,980
Granted Patent B2
US 9,980,980 · App. 14/584,581 · Granted May 29, 2018

Compounds, compositions and methods for protecting brain health in neurodegenerative disorders

Inventors: Christopher L. Rinsch (Morges, CH); Philippe V. Dupraz (Crissier, CH)
Assignee: Amazentis SA
A61K31/7048A23K20/111A23L33/10A23L33/105A61K31/352A61K31/357A61K31/57A61K31/7024A61K36/185C07D493/04C07D493/22C07H13/08C07H15/18C07H15/26A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,980,980
App. No.
14/584,581
Granted
May 29, 2018
Kind
B2
Abstract

Aspects of the invention relate to compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids.

Claims (32)

1. A method for improving memory function, comprising administering to a human in need thereof a therapeutically effective amount of punicalin or punicalagin, or a pharmaceutically acceptable salt of either of them, wherein the therapeutically effective amount is between about 100 mg per day and about 2,500 mg per day, wherein the human does not suffer from cancer.

2. The method of claim 1 , wherein the punicalin or punicalagin is administered as part of a nutraceutical composition, pharmaceutical composition, functional food, functional nutrition product, medical food, medical nutrition product, dietary supplement or botanical drug.

3. The method of claim 1 , wherein punicalin or a pharmaceutically acceptable salt thereof is administered.

4. The method of claim 1 , wherein punicalagin or a pharmaceutically acceptable salt thereof is administered.

5. The method of claim 1 , wherein long-term memory is improved.

6. The method of claim 1 , wherein short-term memory is improved.

7. The method of claim 3 , wherein long-term memory is improved.

8. The method of claim 3 , wherein short-term memory is improved.

9. The method of claim 4 , wherein long-term memory is improved.

10. The method of claim 4 , wherein short-term memory is improved.

11. The method of claim 1 , wherein the therapeutically effective amount is between about 250 mg per day and about 1,000 mg per day.

12. The method of claim 11 , wherein punicalin or a pharmaceutically acceptable salt thereof is administered.

13. The method of claim 11 , wherein punicalagin or a pharmaceutically acceptable salt thereof is administered.

14. The method of claim 11 , wherein long-term memory is improved.

15. The method of claim 11 , wherein short-term memory is improved.

16. The method of claim 12 , wherein long-term memory is improved.

17. The method of claim 12 , wherein short-term memory is improved.

18. The method of claim 13 , wherein long-term memory is improved.

19. The method of claim 13 , wherein short-term memory is improved.

20. A method for decreasing memory loss, comprising administering to a human in need thereof a therapeutically effective amount of punicalin nr punicalagin, or a pharmaceutically acceptable salt of either of them, wherein the therapeutically effective amount is between about 100 mg per day and about 2,500 mg per day, wherein the human does not suffer from cancer.

21. The method of claim 20 , wherein the punicalin or punicalagin is administered as part of a nutraceutical composition, pharmaceutical composition, functional food, functional nutrition product, medical food, medical nutrition product, dietary supplement or botanical drug.

22. The method of claim 20 , wherein punicalin or a pharmaceutically acceptable salt thereof is administered.

23. The method of claim 20 , wherein punicalagin or a pharmaceutically acceptable salt thereof is administered.

24. The method of claim 20 , wherein the memory loss is age-related.

25. The method of claim 22 , wherein the memory loss is age-related.

26. The method of claim 23 , wherein the memory loss is age-related.

27. The method of claim 20 , wherein the therapeutically effective amount is between about 250 mg per day and about 1,000 mg per day.

28. The method of claim 27 , wherein punicalin or a pharmaceutically acceptable salt thereof is administered.

29. The method of claim 27 , wherein punicalagin or a pharmaceutically acceptable salt thereof is administered.

30. The method of claim 27 , wherein the memory loss is age-related.

31. The method of claim 28 , wherein the memory loss is age-related.

32. The method of claim 29 , wherein the memory loss is age-related.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2015
From: RINSCH, CHRISTOPHER L.; DUPRAZ, PHILIPPE V. L.
To: AMAZENTIS SA
Reel/Frame 035330/0018 →
Continuity (3)
Continuation 12842750 · Jul 23, 2010
Provisional Application 61228374 · Jul 24, 2009
Related Publication 20150196577A1 · Jul 16, 2015